Respiratory conditions are prevalent in various forms, which is why delivery methods take on almost as much importance as the drug being used. Issues with delivery and convenience contribute to the reality that many individuals still have poor control of their conditions and continue to live with the symptoms and risks associated with poorly managed respiratory conditions.

In the medium term, Glenmark UK plans to launch more innovative products within respiratory care, candidates across the disease spectrum and devices. This includes our most advanced respiratory candidate Ryaltris™ a fixed dose of olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), formerly GSP 301 nasal spray, which is a combination steroid-antihistamine nasal spray being investigated as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older. “Ryaltris [olopatadine hydrochloride (665 mcg) + Mometasone furoate (25 mcg)] should arrive in the UK soon.

Glenmark’s longer term respiratory pipeline also includes GSP 304, which is a long-acting muscarinic receptor agonist being investigated as a nebulized treatment for COPD; GBR 310, which is a biosimilar for omalizumab being developed as a treatment for asthma and chronic idiopathic urticaria (hives); and GRC 39815, which is being investigated preclinically for the treatment of COPD.

Click here to view our innovative pipeline.